# Gefitinib for EGFR Sensitive Mutation Postoperative Stage Ib NSCLC Patients

> **NCT02526537** · — · TERMINATED · sponsor: **Lunxu Liu** · enrollment: 10 (actual)

## Conditions studied

- NSCLC

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02526537
- **Lead sponsor:** Lunxu Liu
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11-11
- **Primary completion:** 2016-06-07
- **Final completion:** 2016-06-07
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Similar study has revealed result of no benefit for participants
- **Last updated:** 2017-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02526537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02526537, "Gefitinib for EGFR Sensitive Mutation Postoperative Stage Ib NSCLC Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02526537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*